Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 10/26 cls
Affymetrix (AFFX) Piper Jaffray Edward Tenthoff Price target Market perform -6% $25.73
Tenthoff lowered his target to $25 from $26. He also dropped his FY07 and FY08 revenue estimates to $370M from $373M and to $399M from $421M, respectively. Tenthoff also changed his FY07 and FY08 EPS estimates to $0.11 from $0.05 and to $0.55 from $0.58 on AFFX's earnings (see "EPS Watch," A22).
Amgen (AMGN) Baird Christopher Raymond Price target Neutral 2% $57.18
Banc of America Securities William Sargent Other Neutral
CIBC World Markets Bret Holley Other Overweight
Cowen Eric Schmidt Other Market outperform
Leerink William Tanner Other Market outperform
Raymond lowered his target to $56 from $57 and raised his FY07 and FY08 EPS estimates to $4.31 from $4.22 and to $4.46 from $4.38, respectively, on AMGN's earnings. He believes sluggish top-line revenue performance "is likely to drag on AMGN shares for some time to come" (see "EPS Watch," A22).
Sargent lowered his FY07 and FY08 EPS estimates to $2.48 from $3.44 and to

Read the full 1805 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE